Sarah Hurt

Program: Molecular Genetics and Genomics

Current advisor: David T. Curiel, MD, PhD

Undergraduate university: University of Missouri-Columbia, 2019

Enrollment year: 2019

Research summary
Adenoviral gene therapy for MPS I

MPS I is a lysosomal storage disease that is caused by a genetic defect in the IDUA gene with limited treatment options. I am attempting to develop a treatment for MPS I using adenoviral vectors to deliver CRISPR/Cas9 and replace the malfunctioning gene.

Graduate publications
Hurt SC, Dickson PI, Curiel DT. 2021 Mucopolysaccharidoses type I gene therapy. J Inherit Metab Dis, 44(5):1088-98.